CD20+ tumor-infiltrating lymphocytes have an atypical CD27 - memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3281-3292

  Nielsen, Julie S ^a,b   Sahota, Rob A ^a   Milne, Katy ^a   Kost, Sara E ^a   Nesslinger, Nancy J ^a   Watson, Peter H ^a,b   Nelson, Brad H ^a,b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B7 ANTIGEN; CA 125 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NY ESO 1 ANTIGEN; PROTEIN P53; SYNDECAN 1;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DNA SEQUENCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MEMORY CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANTIGEN PRESENTATION; ANTIGENS, CD20; ANTIGENS, CD27; ANTIGENS, CD40; ANTIGENS, CD8; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; AUTOANTIBODIES; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862557227     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0234     Document Type: Article

References (54)

1. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010;29:203-11.
2. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMOClinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2010;21 Suppl 5:v23-30.
3. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101-16. (Pubitemid 351430376)
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. (Pubitemid 36077915)
5. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-5. (Pubitemid 46364164)
6. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4:e6412.
7. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-in filtrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43. (Pubitemid 43011261)
8. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192-8.
9. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-7.
10. Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 2008;108:106-11. (Pubitemid 350299430)
11. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune systemhas a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
12. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 2001;61:7889-99. (Pubitemid 33050986)
13. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating Bcell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 2001;98:12659-64. (Pubitemid 33020002)
14. Hansen MH, Nielsen HV, Ditzel HJ. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 2002;169:2701-11. (Pubitemid 34921019)
15. Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003;63:3275-80. (Pubitemid 36735883)
16. Simsa P, Teillaud JL, Stott DI, Toth J, Kotlan B. Tumor-in filtrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. Pathol Oncol Res 2005;11:92-7. (Pubitemid 41039445)
17. Wang Y, Ylera F, Boston M, Kang SG, Kutok JL, Klein-Szanto AJ, et al. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res Treat 2007;104:129-44. (Pubitemid 47084230)
18. Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, et al. The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J Immunol 2009;182:3310-7.
19. Gnjatic S, Ritter E, Buchler MW, Giese NA, Brors B, Frei C, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010;107:5088-93.
20. Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, et al. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003;104:73-84. (Pubitemid 36184149)
21. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005;238:67-75.
22. Tumanov A, Kuprash D, Lagarkova M, Grivennikov S, Abe K, Shakhov A, et al. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 2002;17:239-50. (Pubitemid 35279546)
23. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
24. Lehnhardt A, Mengel M, Pape L, Ehrich JH, Offner G, Strehlau J. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant 2006;6:847-51. (Pubitemid 43345024)
25. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38. (Pubitemid 36818782)
26. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998;161:3912-8. (Pubitemid 28468965)
27. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8. (Pubitemid 32954353)
28. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284-99. (Pubitemid 351986191)
29. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008;74:664-73.
30. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393-402.
31. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One 2008;3:e3409.
32. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D- J sequence analysis. Nucleic Acids Res 2008;36:W503-8.
33. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009;37:D1006-12.
34. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54. (Pubitemid 28189124)
35. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997;27:2073-9. (Pubitemid 27346026)
36. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-89. (Pubitemid 28516113)
37. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008;20:67-82.
38. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011;118:2150-8.
39. Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 2005;202:783-91. (Pubitemid 41345967)
40. Fecteau JF, Cote G, Neron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 2006;177:3728-36. (Pubitemid 44359905)
41. Wirths S, Lanzavecchia A. ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol 2005;35:3433-41. (Pubitemid 43025524)
42. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977-82.
43. Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL. Impact of myelin-specific antigen presentingBcells on T cell activation in multiple sclerosis. Clin Immunol 2008;128:382-91.
44. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178:6624-33. (Pubitemid 46717447)
45. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 2005;175:2278-85. (Pubitemid 41113835)
46. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, et al. Assessment of the prognostic relevance of serum antip53 antibodies in epithelial ovarian cancer. Gynecol Oncol 1999;72:76-81. (Pubitemid 29045451)
47. Mayerhofer K, Tempfer C, Kucera E, Hefler L, Zeisler H, Kainz C, et al. Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 1999;19:875-8. (Pubitemid 29168348)
48. Vogl FD, Frey M, Kreienberg R, Runnebaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-43.
49. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001;2:1126-32. (Pubitemid 33130146)
50. Kang YM, Zhang X, Wagner UG, Yang H, Beckenbaugh RD, Kurtin PJ, et al. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 2002;195:1325-36. (Pubitemid 34564334)
51. Gnjatic S, Atanackovic D, Matsuo M, Jager E, Lee SY, Valmori D, et al. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol 2003;170:1191-6. (Pubitemid 36139482)
52. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 2008;124:129-40. (Pubitemid 351537580)
53. de Wit J, Souwer Y, Jorritsma T, Klaasse Bos H, ten Brinke A, Neefjes J, et al. Antigen-speci fic B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One 2010;5:e13016.
54. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, et al. Adoptive transfer of tumor reactiveBcells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011;17:4987-95.